Montelukast is used in patients with mild to moderate chronic bronchial asthma when it is not sufficient to treat inhaled glucocorticosteroids and beta-2-sympathomimetics. In this combination, it can also be used to prevent a stress asthma. In contrast, montelukast is not suitable for the treatment of an acute asthma attack.
What is the purpose of this ingredient?
- Extend the airway for asthma
- Reduce mucus secretion in asthma
- reduce inflammatory and allergic reactions in asthma.
That’s how Montelukast
Below you will learn more about the fields of application and the mode of action of montelukast.
Please also read the information on the drug groups to which the active ingredient montelukast belongs.
Applications of the active ingredient Montelukast
Montelukast is used in patients with mild to moderate chronic bronchial asthma, if the treatment with inhaled glucocorticoids and beta-2-sympathomimetics is insufficient. In this combination, it can also be used to prevent a stress asthma. In contrast, montelukast is not suitable for the treatment of an acute asthma attack.
More detailed information is available for the following Montelukast application areas:
Mode of action of Montelukast
Montelukast inhibits the effects of certain proteins (leukotrienes) involved in the development of bronchial asthma, an inflammatory disease of the respiratory tract. In the course of asthma, there is an increase in the formation of viscous mucus, which hinders breathing. Montelukast stops mucus production and thus ensures free airways. This effect is delayed in time, so that montelukast is not effective immediately. For the treatment of an acute asthma attack, the active substance must therefore not be used.
Montelukast has no effect on the inflammatory response itself (such as glucocorticoids) or on the muscles of the bronchi (such as beta-2 sympathomimetics). Therefore, it is always used only in combination with these drug groups.